Access to enantioenriched molecules with diverse fluorinated tetrasubstituted stereocenters using hydroxy as a kinetic resolution auxiliary group-Reference-Cited by-同舟云学术

Access to enantioenriched molecules with diverse fluorinated tetrasubstituted stereocenters using hydroxy as a kinetic resolution auxiliary group

Published:2022 Issue:4 Volume:9 Page:1040-1047
ISSN:2052-4129
Container-title:Organic Chemistry Frontiers
language:en
Short-container-title:Org. Chem. Front.

Author:

Zehra Syeda Tazeen¹,Lan Shouang¹,Zhang Hao¹,Liu Jinggong²^ORCID,Yang Shuang¹,Fang Xinqiang¹^ORCID

Affiliation:

1. State Key Laboratory of Structural Chemistry, and Key Laboratory of Coal to Ethylene Glycol and Its Related Technology, Center for Excellence in Molecular Synthesis, Fujian Institute of Research on the Structure of Matter, University of Chinese Academy of Sciences, Fuzhou 350100, China

2. Orthopedics Department, Guangdong Provincial Hospital of Traditional Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, China

Abstract

We describe in this paper that using secondary OH as the kinetic resolution auxiliary group, a series of previously unavailable fluorinated fully-substituted carbon molecules can be obtained with excellent level of enantioselectivities.

Funder

National Natural Science Foundation of China

Chinese Academy of Sciences

Natural Science Foundation of Fujian Province

Fujian Institute of Research on the Structure of Matter

Publisher

Royal Society of Chemistry (RSC)

Subject

Organic Chemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2022/QO/D1QO01493E

Reference76 articles.

1. I.Ojima , Fluorine in Medicinal Chemistry and Chemical Biology , ed. O. Ojima , Wiley-Blackwell , Chichester , 2009

2. Understanding organofluorine chemistry. An introduction to the C–F bond

3. Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas

4. Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)

5. Fluorine‐Containing Drugs Approved by the FDA in 2018